GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IQVIA (IQV) shares

Learn how to easily invest in IQVIA shares.

IQVIA Holdings Inc is a diagnostics & research business based in the US. IQVIA shares (IQV) are listed on the NYSE and all prices are listed in US Dollars. IQVIA employs 74,000 staff and has a trailing 12-month revenue of around USD$12.9 billion.

How to buy shares in IQVIA

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IQV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted IQVIA's stock price?

Since the stock market crash in March caused by coronavirus, IQVIA's stock price has had significant positive movement.

Its last market close was $257.85, which is 36.62% up on its pre-crash value of $163.43 and 215.26% up on the lowest point reached during the March crash when the stocks fell as low as $81.79.

If you had bought $1,000 worth of IQVIA stocks at the start of February 2020, those stocks would have been worth $540.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,660.55.

Is it a good time to buy IQVIA stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IQVIA shares at a glance

Information last updated 2021-09-10.
Latest market close$257.85
52-week range$146.00 - $265.34
50-day moving average $253.46
200-day moving average $230.06
Wall St. target price$278.16
PE ratio 83.8333
Dividend yield N/A (0%)
Earnings per share (TTM) $3.12

IQVIA stock price (NYSE: IQV)

Use our graph to track the performance of IQV stocks over time.

IQVIA price performance over time

Historical closes compared with the close of $257.85 from 2021-09-16

1 week (2021-09-10) -1.02%
1 month (2021-08-17) 2.66%
3 months (2021-06-17) 4.69%
6 months (2021-03-17) 35.92%
1 year (2020-09-17) 60.65%
2 years (2019-09-17) 68.60%
3 years (2018-09-17) 106.16%
5 years (2016-09-16) 233.53%

Is IQVIA under- or over-valued?

Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IQVIA's P/E ratio

IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 84x. In other words, IQVIA shares trade at around 84x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

IQVIA's PEG ratio

IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1298. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

IQVIA's EBITDA

IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.2 billion.

The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.

IQVIA financials

Revenue TTM $12.9 billion
Operating margin TTM 9.02%
Gross profit TTM $3.9 billion
Return on assets TTM 3.09%
Return on equity TTM 10.85%
Profit margin 4.69%
Book value $30.06
Market capitalisation $50.1 billion

TTM: trailing 12 months

Shorting IQVIA shares

There are currently 2.8 million IQVIA shares held short by investors – that's known as IQVIA's "short interest". This figure is 7.8% up from 2.6 million last month.

There are a few different ways that this level of interest in shorting IQVIA shares can be evaluated.

IQVIA's "short interest ratio" (SIR)

IQVIA's "short interest ratio" (SIR) is the quantity of IQVIA shares currently shorted divided by the average quantity of IQVIA shares traded daily (recently around 797600). IQVIA's SIR currently stands at 3.56. In other words for every 100,000 IQVIA shares traded daily on the market, roughly 3560 shares are currently held short.

However IQVIA's short interest can also be evaluated against the total number of IQVIA shares, or, against the total number of tradable IQVIA shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IQVIA's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IQVIA shares in existence, roughly 10 shares are currently held short) or 0.0149% of the tradable shares (for every 100,000 tradable IQVIA shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IQVIA.

IQVIA's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

IQVIA's total ESG risk score

Total ESG risk: 26.81

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 12/31/2018) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

IQVIA's environmental score

Environmental score: 1.17/100

IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

IQVIA's social score

Social score: 14.76/100

IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

IQVIA's governance score

Governance score: 6.88/100

IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

IQVIA's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.

IQVIA share dividends

We're not expecting IQVIA to pay a dividend over the next 12 months.

IQVIA share price volatility

Over the last 12 months, IQVIA's shares have ranged in value from as little as $146 up to $265.34. A popular way to gauge a stock's volatility is its "beta".

IQV.US volatility(beta: 1.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4214. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

IQVIA overview

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site